Cargando…
Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8768934/ https://www.ncbi.nlm.nih.gov/pubmed/35042825 http://dx.doi.org/10.1136/jitc-2021-004347 |
| _version_ | 1784635024768761856 |
|---|---|
| author | Weber, Jeffrey Mandala, Mario Ascierto, Paolo Antonio Larkin, James |
| author_facet | Weber, Jeffrey Mandala, Mario Ascierto, Paolo Antonio Larkin, James |
| author_sort | Weber, Jeffrey |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8768934 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87689342022-02-04 Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al Weber, Jeffrey Mandala, Mario Ascierto, Paolo Antonio Larkin, James J Immunother Cancer Letter BMJ Publishing Group 2022-01-18 /pmc/articles/PMC8768934/ /pubmed/35042825 http://dx.doi.org/10.1136/jitc-2021-004347 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Letter Weber, Jeffrey Mandala, Mario Ascierto, Paolo Antonio Larkin, James Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al |
| title | Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al |
| title_full | Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al |
| title_fullStr | Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al |
| title_full_unstemmed | Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al |
| title_short | Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al |
| title_sort | response to: association of selected (immune-related) adverse events and outcome in two adjuvant phase iii trials, checkmate-238 and eortc1325/keynote-054 by eggermont et al |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8768934/ https://www.ncbi.nlm.nih.gov/pubmed/35042825 http://dx.doi.org/10.1136/jitc-2021-004347 |
| work_keys_str_mv | AT weberjeffrey responsetoassociationofselectedimmunerelatedadverseeventsandoutcomeintwoadjuvantphaseiiitrialscheckmate238andeortc1325keynote054byeggermontetal AT mandalamario responsetoassociationofselectedimmunerelatedadverseeventsandoutcomeintwoadjuvantphaseiiitrialscheckmate238andeortc1325keynote054byeggermontetal AT asciertopaoloantonio responsetoassociationofselectedimmunerelatedadverseeventsandoutcomeintwoadjuvantphaseiiitrialscheckmate238andeortc1325keynote054byeggermontetal AT larkinjames responsetoassociationofselectedimmunerelatedadverseeventsandoutcomeintwoadjuvantphaseiiitrialscheckmate238andeortc1325keynote054byeggermontetal |